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Abstract
Background: Smoking is common among medically underserved populations. Accessible resources to encourage
and support smoking cessation among these patients are limited. Volunteer medical student-run free smoking
cessation clinics may provide an effective option to help these individuals achieve smoking abstinence. In order to
demonstrate the feasibility and cost-effectiveness of a student-run clinic, we analyzed a case series of patients
receiving care in a medical student-run Smoking Cessation Clinic (SCC) at the Rochester, Minnesota Salvation Army
Good Samaritan Health Clinic (GSHC).
Findings: Between January 2005 and March 2009, 282 cigarette smokers seeking care at the SCC were analyzed.
Student providers at the SCC conducted 1652 weekly individual counseling sessions averaging 18 minutes per
encounter. Patients were offered a choice of pharmacotherapies including nicotine replacement therapy (NRT),
bupropion, and varenicline for up to 12 weeks. Smoking abstinence was confirmed with exhaled carbon monoxide
(CO). Thirty-two patients completed the entire 12-week program (11.3%). At last contact, 94 patients (33.3%)
abstained from smoking for ≥ 7 days and 39 patients (13.8%) were continuously abstinent for ≥ 4 weeks. The
7-day point prevalence abstinence rates at last contact were 58.6% for varenicline, 41.2% for bupropion, 33.9% for
NRT, and 23.5% for bupropion and NRT. Analyzing missing patients as smoking, the 7-day point prevalence
abstinence rates were 7.1%, 8.9%, and 8.2%, at 1 month, 2 months, and 3 months after program enrollment,
respectively. No serious adverse drug reactions were recorded.
Conclusions: Our medical student-run smoking cessation clinic provided an effective and safe experience for
medically underserved patients who might not otherwise have access to conventional smoking cessation programs
because of high cost, lack of insurance, or other disparities. Similar medical student initiatives focusing on healthy
lifestyles may be feasible and beneficial for individuals with limited access to healthcare resources.
Background
Cigarette smoking is the leading cause of preventable
death and disability in the United States. In 2008, 20.8%
of the U.S adult population smoked with much higher
rates among medically underserved and uninsured
populations [1-3]. Among uninsured individuals in an
urban public hospital setting, the smoking prevalence is
65% [4].
Numerous treatments for tobacco dependence exist [5].
Behavioral and pharmacologic approaches have demon-
strated efficacy for increasing tobacco abstinence rates.
Providing treatment for medically underserved popula-
tions, including financially challenged individuals and
those without medical insurance, poses special challenges.
For such individuals, access to conventional healthcare
resources is limited and the cost of pharmaceuticals is
often prohibitive [6-9]. High rates of psychiatric co-
morbidity, substance use, and medical non-adherence
further complicate the delivery of tobacco treatment ser-
vices to underserved populations [10]. Prior investigations
have demonstrated lower smoking cessation success rates
for such populations [11-13].
Medical student-run clinics have been shown to benefit
both the education of the students and the community
serviced by the clinic [14-16]. To increase accessibility to
tobacco use treatment for medically underserved popula-
tions, Mayo Medical School established a free, walk-in
Smoking Cessation Clinic (SCC) in partnership with the
Rochester, Minnesota, Salvation Army. The clinic is
staffed and managed by volunteer medical students * Correspondence: ebbert.jon@mayo.edu
Mayo Clinic, 200 1
st Street Southwest, Rochester, MN 55905, USA
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Health Clinic (GSHC).
In 2001, we reported our preliminary experience at
the clinic and highlighted the feasibility of this care
model [17]. In the current report, we describe the
patient demographics and smoking cessation outcomes
from a large cohort of patients seen at the SCC. We
also present data on the cost of running a student-led
smoking cessation clinic for the medically underserved.
Methods
Study Setting
The Smoking Cessation Clinic (SCC) is in Rochester,
Minnesota, with a catchment area of approximately
140,000 people of whom 89% are white, 3.7% are Afri-
can American, 5% are Asian, and 0.3% are Hispanic
[18]. The current unemployment rate for the commu-
nity is 5.4% [19]. Approximately 8.7% of residents have
no health insurance [20].
The SCC is located in the Rochester Salvation Army’s
Good Samaritan Health Clinic (GSHC). The GSHC was
established in 1995 by the Salvation Army in partner-
ship with Mayo Clinic physicians to voluntarily provide
selected free healthcare services to medically under-
served individuals in the community. Clinic services
include acute care, selected chronic disease management
(e.g., diabetes), dental services, ophthalmologic screen-
ing, and psychiatry/psychology assessment and support.
The study took place between January 2005 and
March 2009. SCC sessions are conducted after hours
one night a week coinciding with acute care clinical
activities of the GSHC. Licensed medical providers and
o n - s i t ep h a r m a c ys e r v i c e so ft h eG S H Ca r ea v a i l a b l et o
SCC student counselors as necessary.
Patient Enrollment
The SCC is advertised to the community with print and
radio advertising. Patients seen by providers in other
GSHC areas (e.g., GSHC Dental Clinic) are referred to
the SCC as appropriate. Although both the SCC and
GSHC are oriented toward providing services to unin-
sured individuals of lower socioeconomic status, all
patients requesting smoking intervention services can
receive services regardless of their financial status, cur-
rent health conditions, or stated motivation to complete
the program.
Individualized Therapy
Medical student volunteers are trained using an appren-
ticeship model with minimal physician intervention.
Experienced second year medical student counselors
train first year volunteer medical student counselors by
modeling SCC interviews. The second year counselors
then observe first year counselors interviewing patients
and provide feedback on provider-patient interactions.
Activities at the SCC are regularly reviewed by a physi-
cian staff specialist of the Mayo Clinic Nicotine Depen-
dence Center.
At the first visit, each patient completes an 8-page
intake questionnaire addressing tobacco use history,
demographic information, and smoking-related or psy-
chiatric health conditions. Patients then meet individually
with a student counselor for approximately 45 minutes so
that the patient and counselor may discuss program
structure, cigarette use history, and other elements of the
intake assessment.
Depression screening is completed using the Center for
Epidemiological Studies - Depressed Mood Scale (CES-
D). This instrument has been found to have good internal
consistency and concurrent validity. It has been shown to
be appropriate for use in populations with a broad range
of demographic characteristics [21]. The intake assess-
ment also includes a detailed checklist to screen for con-
traindications to pharmacotherapy. The checklist of
contraindications is verbally read to each patient to
ensure patient understanding of each question.
Patients are given the option of individual counseling
only or counseling in conjunction with varenicline,
bupropion, and/or nicotine replacement therapy (NRT).
Patients who request and qualify for NRT receive their
choice of a 7-day supply of patches, gum, lozenges,
inhalers, or nasal spray according to their preferences
on the first intake visit. Medical prescriptions are signed
by an on-site licensed volunteer GSHC provider. Intake
assessment and management plans for all enrolled sub-
jects are reviewed and approved by a physician specialist
of the Mayo Clinic Nicotine Dependence Center. Finan-
cial support is provided by Mayo Clinic and medications
are supplied by pharmaceutical companies.
Patients are invited to return to the SCC for weekly
follow-up counseling sessions for the next 12 weeks of
the program. During these 15-30 minute sessions, coun-
selors discuss management of cravings and withdrawal
symptoms as well as encourage patients to make lifestyle
modifications in order to address the behavioral aspects
of smoking addiction. Appropriate medication use and
potential adverse effects are reviewed with the patient
and pharmacotherapy is modified as necessary. Finally,
counselors partner with patients to establish weekly
goals for continued progress towards complete smoking
cessation. At the end of each session, the counselors
complete a weekly follow-up form documenting the
patient’s smoking cessation progress, motivation, and
medication side effects. An additional 7-day supply of
the appropriate medication is dispensed if requested by
the patient, and the patient is encouraged to return the
following week. Patients were requested to return for
weekly sessions for 12 weeks. At the end of 12 weeks,
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medications as appropriate.
Data Collection
Each subject completes general research authorization
during their first visit with the understanding that refu-
sal to authorize research participation does not affect
their current or future care at either the SCC or the
G S H C .M i n o r s( i . e . ,a g e<1 8y e a r s )a n dt h o s ew h o
refused participation are excluded from the current ana-
lysis. Participant charts were abstracted for sociodemo-
graphic data, smoking history, and program progress.
Self-reported abstinence was biochemically confirmed by
counselors with exhaled carbon monoxide (CO).
Statistical Methods
Baseline patient demographic information, health his-
tory, and tobacco use patterns were recorded at initial
intake. Clinic utilization data, patient tobacco use, and
dispensed medication were recorded from weekly fol-
low-up forms. Descriptive statistics were used to com-
pile means, standard deviations (SDs), frequencies, and
percentages for all enrolled subjects. The number and
percentage of patients given each medication were cal-
culated as the number/percentage of patients who
received that medication during the course of their ther-
apy even if they later switched to a different medication.
Smoking abstinence was defined as 7-day point preva-
lence abstinence (i.e., no smoking, not even a puff in the
last 7 days) and continuous abstinence (i.e., no smoking
for ≥ 4 weeks) prior to their last contact with SCC.
Abstinence rates were compiled for the entire study
population and time period. Subgroup analyses were
conducted in order to test for the effect of the release of
varenicline on smoking abstinence rates, to examine
temporal trends in patient abstinence rates on a yearly
basis, and to examine the effects of each treatment type
on abstinence rates. Specifically, subgroup analyses
included abstinence rates for: 1) the study population
before and after February 2006, the date on which vare-
nicline became available for use at the SCC; 2) each
individual year from 2005-2008; and 3) each treatment
type (varenicline, bupropion alone, NRT alone, or a
combination of bupropion and NRT). Abstinence rates
for each treatment type were calculated as the percen-
tage of patients abstinent at the time of last contact out
of the total number of patients who took that treatment
type. Abstinence rates were calculated for treatment
type such that an individual subject could be counted in
two different treatment groups if they received more
than one type of therapy over the study timeframe.
Abstinence rates were also calculated for the total
patient population using an intention-to-treat analysis
for 1-month, 2-month and 3-month time points since
p r o g r a me n r o l l m e n ti nw h i ch all patients who did not
return for their appointments were counted as smoking.
To test for demographic characteristic differences
among smokers who chose different treatment plans, we
conducted ANOVA analysis for continuous baseline
variables (age and cigarettes smoked per day at the
beginning of treatment) as well as a chi-square test for
categorical variables (sex and motivation level).
Although there were 5 treatment groups, there were
very few people who received bupropion alone (n = 1).
We restricted this analysis to patients who were only on
bupropion+NRT and never switched to any other ther-
apy (n = 5). Therefore, when comparing the other base-
line variables across treatment groups, we eliminated
these groups and compared the variables across the
other 3 treatment groups (varenicline, NRT, and combi-
nation therapy). Combination therapy was defined as a
patient who began treatment with one medication but
later changed to a different medication during the
course of treatment.
Yearly budgets for 2005, 2006, 2007, and 2008 were cal-
culated based on the average cost of medication distribu-
ted to patients for that year. The average cost-per-quit
was calculated by averaging the yearly cost of running
the clinic by the number of patients with 7-day point pre-
valence smoking abstinence at their 3-month time point
since program enrollment adjudicating all patients not
present as smoking.
Results
Demographic Data
Of 282 cigarette smokers who sought care at the SCC
between January 2005 and March 2009, charts could be
abstracted for baseline demographics and tobacco use
h i s t o r yd a t af o r2 5 7p a t i e n t s( T a b l e1 ) .O v e ras i x
month period in 2008-2009, the SCC saw an average of
six patients per week. Extrapolating this data across Jan-
uary 2005 to March 2009, approximately 1320 patients
were treated of which 21.4% (282) participated in the
study. The average age of smokers was 42 years (SD ±
13.1) and 45% were female. Patients smoked an average
of 27 cigarettes per day (SD ± 14.5) and had been smok-
ing for an average of 24 years (SD ± 12.1 years).
A majority of patients (74.6%; n = 192) reported at
least one smoking related medical condition and were
coping with at least one major stressor in their lives
(72.4%; n = 186). Nearly one-half of patients received
formal treatment for major depression and a third of
patients reported “feeling sad” for most of that year.
Almost all patients reported consuming alcohol at one
point in their life (96.1%; n = 247) and over one-quarter
of patients felt that they needed to decrease their alco-
hol intake (26.1%; n = 67). Over one-quarter of patients
had also entered into a formal treatment program for
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N (%) N (%)
Men 140 (54.5) Other Smoker in Household 67 (26.1)
Women 113 (44)
Education Tobacco Products
<8th grade 3 (11.7) Cigarettes 251 (97.7)
>8th grade 2 (0.1) Pipe 1 (0.1)
Some High School 18 (7) Cigar 6 (2.3)
High School Degree 101 (39.3) Snuff 2 (0.1)
Technical Degree 75 (29.2) Chew 6 (2.3)
College Degree 41 (15.9) Major Stressors
Graduate Degree 8 (3.2) Death 30 (11.7)
Other 3 (1.2) Loss of relationship 25 (9.2)
Employment Divorce/Separation 17 (6.6)
Health Care 15 (5.8) Health 57 (22.2)
Professional 11 (4.3) Job 28 (10.9)
White Collar 29 (11.3) Move 19 (7.4)
Blue Collar 67 (26.1) Legal 17 (6.6)
Homemakers 4 (1.5) Other 68 (26.5)
Unemployed 55 (21.4) None 71 (27.7)
Retired 14 (5.4) Depression
Student 13 (5.1) >2 wks/yr with sad feelings 108 (42)
Other 49 (19.1) >2 yrs with sad feelings 90 (35.1)
Ethnicity Sad most of this year 77 (30)
Native American 9 (3.5) Treated for depression 117 (45.5)
Asian 0 Motivation
African American 9 (3.5) None 0
Hispanic 4 (1.6) Some 45 (17.5)
White 227 (88.0) Very 205 (79.8)
Other 1 (0.1) Previous Cessation Techniques
Medical History/Complaints Abrupt cessation 152 (59.1)
Angina 13 (5.1) Self-help 55 (21.4)
Asthma 59 (23) Counseling 30 (11.7)
Cancer 16 (6.2) Reduction 78 (30.3)
Chest Pain 57 (22.2) Hypnosis 29 (11.3)
Bronchitis 49 (19.1) Acupuncture 9 (3.5)
Diabetes 17 (6.6) Formal program 22 (8.6)
Emphysema 16 (6.2) Inpatient program 4 (1.6)
Cough/Chest Colds 84 (32.7) Nicotine gum 93 (36.2)
MI 11 (4.3) Nicotine patches 153 (59.5)
Morning Cough 133 (52) Bupropion 80 (31.1)
Other 3 (1.2) Group therapy 9 (3.5)
Nicotine nasal spray 6 (2.3)
Nicotine inhaler 54 (21)
* Data is from January 2005 - March 2009 (N = 257).
± All patients who used another form of tobacco other than cigarettes also concurrently used cigarettes.
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patients stated that they had been drug free for greater
than one year at the time of initial treatment (93.4%;
n = 240).
In general, the patient population self-reported that
they were highly motivated to quit smoking (79.8%; n =
205). Most patients had a desire to quit for >1 year
(56%; n = 144) and most patients (69.3%; n = 164) had
made at least 2 to 5 quit attempts in the past.
Treatment and Follow-Up
Patients could receive more than one type of medication
therapy. Among the patients receiving pharmacotherapy
(N = 282), 60.0% (n = 169) of patients received vareni-
cline, 40.0% (n = 112) received NRT alone, 12.1% (n =
34) received combination therapy with bupropion and
NRT, and 6.0% (n = 17) received bupropion alone. No
significant differences were observed between treatment
groups for any of the characteristics evaluated (sex p =
0.30, motivation p = 0.95, age p = 0.13, cigarettes per
day p = 0.22).
Smoking Abstinence
Of 282 patients, 94 (33.3%) successfully quit smoking for
≥ 7 days prior to last contact and 39 (13.8%) were con-
tinuously abstinent for ≥ 4 weeks at time of last contact.
Although only 54.3% (n = 153) of patients attended the
fourth treatment session, 29.8% (n = 84) of the patients
successfully abstaining from smoking had quit by one
month after initial consultation. Almost one-third
(28.7%; n = 81) of patients did not return after their sec-
ond visit.
Before the clinic began offering varenicline in February
2006, 83 patients received treatment at SCC of whom
1 8 . 0 %( n=1 5 )s u c c e s s f u l l ya b s t a i n e df r o ms m o k i n g≥
7 days at last contact. After the clinic began dispensing
varenicline, 199 patients were treated at SCC before
March 2009 of whom 39.7% (n = 79) achieved 7-day
point prevalence smoking abstinence at last contact.
The overall clinic 7-day point prevalence smoking
abstinence rates at last contact were as follows: 19.2% in
2005 (14/73 patients); 22.2% in 2006 (16/72 patients);
42.9% in 2007 (36/84 patients); and 46.9% in 2008 (23/
49 patients).). The 7-day point prevalence abstinence
rates for the different medications were as follows:
58.6% (99/169 patients) for varenicline; 41.1% (7/17
patients) for bupropion alone; 33.9% (38/112 patients)
for NRT alone; and 23.5% (8/34 patients) for bupropion
and NRT.
Abstinence rates were also determined at monthly
time points for program participation. Of 113 patients
seen at their 1-month follow-up visit, 20% (n = 23)
achieved 7-day point prevalence smoking abstinence. Of
56 patients presenting for their 2-month follow-up visit,
25% (n = 14) were abstinent. Of the 40 patients present-
ing for their 3-month follow-up, 23% (n = 9) were absti-
nent. Of the entire patient population with subjects not
returning adjudicated as smoking, the 7-day point preva-
lence abstinence rates for 1-, 2-, and 3-month follow up
visits were 7.1% (n = 20), 8.9% (n = 25), and 8.2% (n =
23), respectively.
We also analyzed correlations between patient demo-
graphics and attendance at counseling sessions. While
25.7% (n = 44) of the 169 patients who returned for
their third visit had received treatment for illicit drug
use, 35.7% (n = 30) of the 84 patients not returning for
their third visit had received treatment. Similarly, while
100% of those patients who returned for their third visit
had been abstinent from illegal drugs for >1 year, only
80% (n = 67) of those not returning had been abstinent.
Budget
The total budget spent on medication given to SCC
patients during the study time period was $51,272. The
yearly budgets for 2005, 2006, 2007, and 2008 were
$8,615, $12,234, $20,396, and $10,027, respectively. The
average cost per successfully abstinent patient at the
3-month time point was $1231, $1529, $2266, and
$1671 for 2005, 2006, 2007, and 2008 respectively.
Discussion
We observed that a student-run smoking cessation
clinic is feasible and can facilitate smoking abstinence
among medically underserved populations. One-third of
the patients were abstinent from smoking at last con-
tact. Although the drop-out rate was high, 54.4% of
patients attended at least four treatment sessions.
Our smoking cessation clinic run by medical students
achieved 7-day point prevalence and long-term absti-
nence rates comparable to those reported for other con-
ventional treatment programs [22-24]. We believe that
these results are notable given that they were achieved
in a medically underserved population with demo-
graphic predictors of non-adherence such as high rates
of psychiatric illness, substance abuse, and serious health
conditions.
In an attempt to be consistent with the rest of the
tobacco treatment literature, we have adjudicated sub-
jects lost to follow-up as smoking. This is a conservative
estimate and we recognize that this likely underesti-
mates the true tobacco abstinence rate. However, this
conservative estimate underscores the critical impor-
tance of increasing the focus on tobacco use among
underserved populations who represent the demo-
graphic with the highest prevalence of use. Benowitz
et al. noted that active smoking was particularly high
among African American populations (77%), the unin-
sured (65%), self-reported alcohol drinkers (77%), and
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San Francisco [4]. Public health efforts should continue
to direct resources to the treatment of tobacco use in
this group in order to decrease the tremendous death
and disability caused by tobacco use and dependence.
Our results were accomplished within a reasonable
budget. Our cost per patient who had abstained from
smoking for 7 or more days at 3 months since initiation
of treatment was between $1000-2000. This figure com-
pares favorably to the $2000-3000 cost-per-quit figures
previously published [25,26]. The cost-effectiveness of
the clinic may be partially attributable to the provision
of individualized counseling and the incorporation of
the cost-effective medication varenicline at no charge to
patients.
The feasibility of our clinic was initially reported in
2001 [17]. Results from the current analysis demonstrate
marked improvement in abstinence rates with successive
years of clinic operation. Incorporation of varenicline
into our therapeutic armamentarium could certainly
have contributed to this finding. Prior investigations
h a v es u g g e s t e dt h a tv a r e n i c l i n em a yb eam o r ee f f e c t i v e
smoking cessation adjunct for some populations [27].
However, the addition of varenicline in February 2006,
does not temporally correlate with the 20% increase in
7-day point prevalence abstinence rates at the time of
last patient contact from only 22.2% in 2006 (16/72
patients) to 42.9% in 2007 (36/84 patients). It is possible
that this delayed increase in abstinence rates may be
related to delayed adoption of varenicline as a com-
monly prescribed pharmacotherapy. However, we sug-
gest that the “apprenticeship” model used to orient new
counselors may have contributed to the long-term suc-
cess and improvement of the clinic over time. New
counselors are oriented through a protocol that incorpo-
rates interview modeling, shadowing, and direct observa-
tion with pointed feedback on initial counselor-client
interactions by a seasoned student provider. This
method provides the opportunity for new counselors to
learn from the experience of previous counselors,
thereby continually improving the operation of the
clinic. It also provides the experienced counselor with a
teaching opportunity to pass on acquired knowledge.
Reports of other student-staffed endeavors support the
value of learning by this means [17,28,29].
We observed that the abstinence rates with the combi-
nation of NRT and bupropion were lower than with
bupropion alone. In our clinic, counselors and subjects
agree on treatment plans that are tailored for individual
patients. We hypothesize that subjects selecting bupro-
pion+NRT have relapsed with other drug regimens and
are more tobacco-dependent resulting in lower observed
abstinent rates on the combination.
Particular strengths of this study include the longevity
of the clinic (14 years), the large number of enrolled
subjects, a multi-faceted treatment plan (counseling and
medication therapy), a reasonable budget, and biochemi-
cally-confirmed smoking abstinence.
Our study has several limitations. First, this is a retro-
spective cohort study. Since only patients who signed
the consent form were included, data from patients with
less motivation to both quit and participate in our
research study may have increased our observed absti-
nence rates. Secondly, the design of the current trial
does not allow us to draw any conclusions about the
effect of a particular medication or treatment approach
in this population of tobacco users. Patients were able
to select the medications they used which may have
improved adherence leading to improved efficacy. Our
careful screening procedures prevented patients with a
psychiatric history from receiving varenicline which may
have elevated the observed abstinence rates among
patients receiving varenicline. Third, abstinence rates
were challenging to ascertain in this patient population
because of the high drop out rate and skipped visits. As
a result, we submit that the most informative efficacy
rate for this study may be the reported 7-day point pre-
valence abstinence rates at the time of last patient con-
tact with SCC. We selected the 7-day point prevalence
abstinence rate to be consistent with the medical litera-
ture. However, this index captures only a one week win-
dow in the experience of a smoker attempting to
become tobacco free and this measure may be an inade-
quate predictor of long-term abstinence. This estimate
also includes a more heterogeneous population of smo-
kers such as smokers who have quit for one week and
smokers who have quit for one month unlike other
measures such as continuous abstinence [30]. Finally,
while we are not aware of any investigations demon-
strating the efficacy of the mentor modeling teaching
method in medical students, studies have shown that
both peer mentoring and supervisor mentoring are suc-
cessful in other populations [31,32]. Our cost analysis is
limited by: 1) only the cost of medication actually dis-
tributed to patients was included and undistributed
medications lost to expiration were not included; and
2) much of the medication used by patients at the SCC
was donated by pharmaceutical companies.
We submit that the SCC has been successful in two
primary ways: 1) the observed smoking abstinence rates
among an underserved population are comparable to
those observed in other studies; and 2) the clinic was a
public service conducted by medical students reaching
populations who would otherwise not have received these
services allowing for new learning opportunities for medi-
cal students. Factors that may have contributed to the
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and location (i.e., after normal business hours, in a medi-
cal clinic located in a subsidized housing unit, near public
transportation); 2) dynamic program that includes free
weekly, individualized counseling sessions with dedicated
and experienced counselors; and 3) free access to the
spectrum of currently recommended smoking cessation
medication. These strategies effectively eliminate some of
the major barriers to smoking cessation treatment for
medically underserved patient populations.
Conclusions
Our study supports the feasibility and efficacy of a free,
medical student led smoking cessation clinic with physi-
cian training involvement, a dedicated physician to over-
see prescription management, and proper funding. It
may serve as a model upon which future medical stu-
dent-run free smoking cessation clinic endeavors could
be based. Such endeavors have the potential to provide
both an educational benefit to the student and a valued
healthcare service to the community.
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